Clinton Rayhill
Psychiatric/Mental Health · Louisville, KYNPI 1700330008
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 540 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,727 and has fallen 85.4% since, to $399 in 2025. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 540 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Bausch Health US, LLC$932
- Lundbeck LLC$752
- Alkermes, Inc.$611
- Otsuka America Pharmaceutical, Inc.$456
- plus $4K from 20 others
What the payments were for
- Food & beverage$8,979100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,349 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $1,144 |
| Bausch Health US, LLC | 71 | $932 |
| Lundbeck LLC | 36 | $752 |
| Alkermes, Inc. | 39 | $611 |
| Otsuka America Pharmaceutical, Inc. | 26 | $456 |
| Corium, LLC | 31 | $420 |
| Ironshore Pharmaceuticals Inc. | 27 | $389 |
| Vanda Pharmaceuticals Inc. | 15 | $376 |
| Tris Pharma Inc | 16 | $374 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $338 |
| Supernus Pharmaceuticals, Inc. | 12 | $335 |
| Noven Therapeutics, LLC | 17 | $314 |
| Axsome Therapeutics, Inc. | 14 | $292 |
| Sunovion Pharmaceuticals Inc. | 18 | $284 |
| Johnson & Johnson | 7 | $134 |
| Teva Pharmaceuticals USA, Inc. | 7 | $131 |
| Neos Therapeutics, LP | 7 | $103 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Almatica Pharma LLC | 3 | $45 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
| Tempus AI, Inc | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$250
- Dyanavel XR$125
- Quillichew ER$125
- Quillivant$125
- VRAYLAR$125
How this compares
$9,007 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate ErMethylphenidate Hcl | 13 | $6,121 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $3,028 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 50 | $1,856 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,791 |
| Duloxetine Hcl | 51 | $1,516 |
| Quetiapine Fumarate | 24 | $698 |
| Ziprasidone Hcl | 11 | $646 |
| Alprazolam | 65 | $626 |
| Bupropion XlBupropion Hcl | 25 | $509 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $382 |
| Prazosin Hcl | 14 | $381 |
| Escitalopram Oxalate | 23 | $370 |
| Clonazepam | 90 | $344 |
| Buspirone Hcl | 36 | $322 |
| Sertraline Hcl | 22 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $45 | $31422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Louisville
- Denise de AngelisLouisville$384K
- Mark BushLouisville$52K
- Harold O'BrienLouisville$28K
- Shane WattsLouisville$13K
- Michelle LoseLouisville$7K
- Ryan HopsonLouisville$7K
- Kimberly ViltLouisville$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Jennifer SampangCrestview Hills$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.